Phase 2 N=9 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Merkel Cell Carcinoma
Primary: MLN01283 Maximum Tolerated Dose (MTD) [Phase I] — 3 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=204 Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Carcinoma, Merkel Cell
Primary: Part A: Number of Participants With Confirmed Best Overall Response (BOR) as Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 — 10; 19; 9; 0…
Phase 2 N=50 Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Recurrent Merkel Cell Carcinoma · Stage III Merkel Cell Carcinoma AJCC v7 · Stage IIIA Merkel Cell Carcinoma AJCC v7
Primary: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation…
Phase 3 N=55 Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
Merkel Cell Carcinoma
Primary: Objective Response Rate (ORR) — 49.1 Percentage of participants
Phase 2 N=9 Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
Advanced Merkel Cell Carcinoma · Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) — 7.5; 5.5 months
Phase 2 N=15 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Merkel Cell Carcinoma
Primary: Percentage of Participants Who Experienced At Least 2-Fold Increase in Expression of IL-12 Protein in the Tumor Tissue After Intratumoral (IT) pIL-12 Injections and In…
Phase 2 N=107 A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Metastatic Merkel Cell Carcinoma
Primary: Objective Response Rate (ORR) — 52.3 percentage of participants
Phase 2 N=19 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Melanoma · Merkel Cell Carcinoma · Other Solid Tumors
Primary: Best Response — 1; 1; 0; 0 Participants
Phase 2 N=17 Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Medullary Thyroid Cancer (MTC)
Primary: Clinical Response — 0; 0 Participants
Phase 3 N=102 Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants
Phase 3 N=450 Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Carcinoma, Squamous Cell
Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243
Phase 2 N=40 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin
Skin Cancer
Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=16 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Skin Basal Cell Carcinoma
Primary: Overall Response Rate (ORR) — 44; 29 Percentage of participants
Phase 2 N=15 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 4 N=35 VISmodegib for ORbital and Periocular Basal Cell Carcinoma
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Phase 2 N=8 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
Phase 2 N=20 Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
Carcinoma, Basal Cell
Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale
Phase 2 N=11 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Recurrent Skin Carcinoma · Skin Squamous Cell Carcinoma
Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants
Phase 3 N=120 Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle — 92; 90 percentage of…
Phase 2 N=9 Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides
Mycosis Fungoides · Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
Primary: Proportion of Overall Cutaneous Responders at Their 9th or Final Cycle (Cutaneous Complete Response [CR], Cutaneous 90 Response [CR90] or Cutaneous Partial Response…
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Phase 2 N=21 Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) — 0; 0 Participants
Phase 2 N=23 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
Recurrent Skin Cancer · Squamous Cell Carcinoma of the Skin
Primary: Early Progression Rate — 31.8 percentage of participants
Phase 2 N=159 Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)
Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) — 35.2; 51.9 Percentage of participants